NASDAQ:EOLS Evolus (EOLS) Stock Price, News & Analysis $7.63 +0.11 (+1.46%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$7.64 +0.01 (+0.13%) As of 08/29/2025 06:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Evolus Stock (NASDAQ:EOLS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Evolus alerts:Sign Up Key Stats Today's Range$7.44▼$7.6650-Day Range$5.77▼$9.7352-Week Range$5.71▼$17.82Volume472,060 shsAverage Volume2.26 million shsMarket Capitalization$493.51 millionP/E RatioN/ADividend YieldN/APrice Target$21.25Consensus RatingModerate Buy Company Overview Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California. Read More Evolus Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks83rd Percentile Overall ScoreEOLS MarketRank™: Evolus scored higher than 83% of companies evaluated by MarketBeat, and ranked 168th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingEvolus has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageEvolus has only been the subject of 3 research reports in the past 90 days.Read more about Evolus' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Evolus are expected to grow in the coming year, from ($0.61) to ($0.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Evolus is -7.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Evolus is -7.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Evolus' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted22.15% of the float of Evolus has been sold short.Short Interest Ratio / Days to CoverEvolus has a short interest ratio ("days to cover") of 9.6.Change versus previous monthShort interest in Evolus has recently increased by 6.73%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEvolus does not currently pay a dividend.Dividend GrowthEvolus does not have a long track record of dividend growth. Sustainability and ESG3.5 / 5Environmental Score-1.27 Percentage of Shares Shorted22.15% of the float of Evolus has been sold short.Short Interest Ratio / Days to CoverEvolus has a short interest ratio ("days to cover") of 9.6.Change versus previous monthShort interest in Evolus has recently increased by 6.73%, indicating that investor sentiment is decreasing significantly. News and Social Media4.0 / 5News Sentiment1.18 News SentimentEvolus has a news sentiment score of 1.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.05 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Evolus this week, compared to 5 articles on an average week.Search Interest2 people have searched for EOLS on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows1 people have added Evolus to their MarketBeat watchlist in the last 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Evolus insiders have sold 236.83% more of their company's stock than they have bought. Specifically, they have bought $393,600.00 in company stock and sold $1,325,764.00 in company stock.Percentage Held by InsidersOnly 5.90% of the stock of Evolus is held by insiders.Percentage Held by Institutions90.69% of the stock of Evolus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Evolus' insider trading history. Receive EOLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evolus and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EOLS Stock News HeadlinesInsider Selling: Evolus (NASDAQ:EOLS) CMO Sells 5,722 Shares of StockAugust 27 at 7:20 AM | insidertrades.comEvolus, Inc. (NASDAQ:EOLS) Director Acquires $204,600.00 in StockAugust 19, 2025 | insidertrades.comTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes. | Porter & Company (Ad)Evolus announces Evolysse Sculpt trial meets primary endpointAugust 25, 2025 | msn.comEvolus Announces Positive Data From Pivotal Trial for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product at 2025 Cosmetic BootcampAugust 25, 2025 | businesswire.comEvolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel ProductAugust 20, 2025 | businesswire.comEvolus Appoints New Principal Financial OfficerAugust 15, 2025 | theglobeandmail.comEvolus (EOLS) Q2 Revenue Rises 4%August 15, 2025 | theglobeandmail.comSee More Headlines EOLS Stock Analysis - Frequently Asked Questions How have EOLS shares performed this year? Evolus' stock was trading at $11.04 at the beginning of 2025. Since then, EOLS stock has decreased by 30.9% and is now trading at $7.63. How were Evolus' earnings last quarter? Evolus, Inc. (NASDAQ:EOLS) posted its quarterly earnings results on Tuesday, March, 23rd. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by $0.18. The business earned $20.58 million during the quarter, compared to the consensus estimate of $20.60 million. Evolus had a negative trailing twelve-month return on equity of 759.04% and a negative net margin of 22.31%. Read the conference call transcript. When did Evolus IPO? Evolus (EOLS) raised $65 million in an IPO on Thursday, February 8th 2018. The company issued 5,000,000 shares at $12.00-$14.00 per share. Cantor and Mizuho Securities acted as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers. Who are Evolus' major shareholders? Evolus' top institutional shareholders include Perceptive Advisors LLC (3.83%), Frazier Life Sciences Management L.P. (3.77%), Soleus Capital Management L.P. (3.28%) and Frontier Capital Management Co. LLC (2.57%). Insiders that own company stock include Alphaeon 1 Llc, Medytox Inc, David Moatazedi, Rui Avelar, Vikram Malik, Sandra Beaver, Tomoko Yamagishi-Dressler, Brady Stewart, Albert G White III, David N Gill, David N Gill and Robert Hayman. View institutional ownership trends. How do I buy shares of Evolus? Shares of EOLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Evolus own? Based on aggregate information from My MarketBeat watchlists, some other companies that Evolus investors own include American Water Works (AWK), Humana (HUM), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AU Optronics (AUOTY). Company Calendar Last Earnings3/23/2021Today8/30/2025Next Earnings (Estimated)11/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED PRODUCTS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:EOLS CIK1570562 Webwww.evolus.com Phone(949) 284-4555FaxN/AEmployees170Year FoundedN/APrice Target and Rating Average Price Target for Evolus$21.25 High Price Target$25.00 Low Price Target$18.00 Potential Upside/Downside+178.5%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($0.98) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$50.42 million Net Margins-22.31% Pretax Margin-22.05% Return on Equity-759.04% Return on Assets-24.63% Debt Debt-to-Equity Ratio22.00 Current Ratio2.27 Quick Ratio1.86 Sales & Book Value Annual Sales$266.27 million Price / Sales1.85 Cash FlowN/A Price / Cash FlowN/A Book Value($0.29) per share Price / Book-26.31Miscellaneous Outstanding Shares64,680,000Free Float60,869,000Market Cap$493.51 million OptionableOptionable Beta1.12 Social Links Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:EOLS) was last updated on 8/30/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evolus, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evolus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.